 EMERYVILLE, Calif., Nov. 16, 2020 GLOBE NEWSWIRE -- XOMA Corporation Nasdaq: XOMA XOMA or the Company today announced it has earned a 2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab TAK-079 in participants with generalized myasthenia gravis MG. In 2006, XOMA and Takeda entered into a collaboration agreement to identify potential therapeutic antibodies that Takeda would advance into clinical development. Mezagitamab is an anti-CD38 antibody that resulted from the companies collaboration. 